Adjuvant activity mediated by iNKT cells

Seminars in Immunology

Volumn 22, Issue 2, 2010, Pages 97-102

  Fujii, Shinichiro ^a   Motohashi, Shinichiro ^b   Shimizu, Kanako ^a   Nakayama, Toshinori ^b   Yoshiga, Yohei ^a   Taniguchi, Masaru ^a  

^a RIKEN Center for Integrative Medical Sciences   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Galactosylceramide; Adjuvant effects; Clinical trial; Dendritic cells; iNKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD40 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS 2 GLYCOPROTEIN D; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN; MALARIA VACCINE; OVALBUMIN; TOLL LIKE RECEPTOR; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONING; CELL MATURATION; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; GENITAL HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; INNATE IMMUNITY; INVARIANT NATURAL KILLER T CELL; LEISHMANIASIS; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE CULTURE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTASIS INHIBITION; NATURAL KILLER T CELL; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GALACTOSYLCERAMIDES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERFERON-GAMMA; LUNG NEOPLASMS; NATURAL KILLER T-CELLS; NEOPLASM METASTASIS;

EID: 77649237008     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2009.10.002     Document Type: Review

References (49)

1. Taniguchi M., Harada M., Kojo S., Nakayama T., and Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21 (2003) 483-513
2. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., and Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 4 (2004) 231-237
3. Bendelac A., Savage P.B., and Teyton L. The biology of NKT cells. Annu Rev Immunol 25 (2007) 297-336
4. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
5. Spada F.M., Koezuka Y., and Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188 (1998) 1529-1534
6. Brossay L., Chioda M., Burdin N., Koezuka Y., Casorati G., Dellabona P., et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188 (1998) 1521-1528
7. Brigl M., and Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 22 (2004) 817-890
8. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163 (1999) 4647-4650
9. Eberl G., and MacDonald H.R. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 30 (2000) 985-992
10. Gumperz J.E., Miyake S., Yamamura T., and Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195 (2002) 625-636
11. Hayakawa Y., Takeda K., Yagita H., Smyth M.J., Van Kaer L., Okumura K., et al. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 100 (2002) 1728-1733
12. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J Exp Med 198 (2003) 267-279
13. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171 (2003) 5140-5147
14. Shimizu K., Goto A., Fukui M., Taniguchi M., and Fujii S. Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 178 (2007) 2853-2861
15. Fujii S. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol 29 (2008) 242-249
16. Fujii S., Shimizu K., Kronenberg M., and Steinman R.M. Prolonged interferon-g producing NKT response induced with α-galactosylceramide-loaded dendritic cells. Nat Immunol 3 (2002) 867-874
17. Fujii S., Liu K., Smith C., Bonito A.J., and Steinman R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199 (2004) 1607-1618
18. Matsuda J.L., Gapin L., Baron J.L., Sidobre S., Stetson D.B., Mohrs M., et al. Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 100 (2003) 8395-8400
19. Kitamura H., Iwakabe K., Yahata T., Nishimura S., Ohta A., Ohmi Y., et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189 (1999) 1121-1128
20. + NKT cell-mediated anti-tumor responses and their clinical application. Springer Semin Immunopathol 27 (2005) 65-74
21. Kawamura T., Takeda K., Mendiratta S.K., Kawamura H., Van Kaer L., Yagita H., et al. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 160 (1998) 16-19
22. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., and Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201 (2005) 1973-1985
23. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202 (2005) 1279-1288
24. + natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 220 (2007) 183-198
25. Liu K., Iyoda T., Saternus M., Kimura K., Inaba K., and Steinman R.M. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196 (2002) 1091-1097
26. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195 (2002) 617-624
27. Akutsu Y., Nakayama T., Harada M., Kawano T., Motohashi S., Shimizu E., et al. Expansion of lung Vα14 NKT cells by administration of α-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 93 (2002) 397-403
28. Motohashi S., Kobayashi S., Ito T., Magara K.K., Mikuni O., Kamada N., et al. Preserved IFN-γ production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer 102 (2002) 159-165
29. Liu K., Idoyaga J., Charalambous A., Fujii S., Bonito A., Mordoh J., et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202 (2005) 1507-1516
30. Youn H.J., Ko S.Y., Lee K.A., Ko H.J., Lee Y.S., Fujihashi K., et al. A single intranasal immunization with inactivated influenza virus and α-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25 (2007) 5189-5198
31. Kamijuku H., Nagata Y., Jiang X., Ichinohe T., Tashiro T., Mori K., et al. Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 1 (2008) 208-218
32. Kopecky-Bromberg S.A., Fraser K.A., Pica N., Carnero E., Moran T.M., Franck R.W., et al. α-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27 (2009) 3766-3774
33. Guillonneau C., Mintern J.D., Hubert F.X., Hurt A.C., Besra G.S., Porcelli S., et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 106 (2009) 3330-3335
34. Lindqvist M., Persson J., Thorn K., and Harandi A.M. The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 182 (2009) 6435-6443
35. Dondji B., Deak E., Goldsmith-Pestana K., Perez-Jimenez E., Esteban M., Miyake S., et al. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38 (2008) 706-719
36. Huang Y., Chen A., Li X., Chen Z., Zhang W., Song Y., et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine 26 (2008) 1807-1816
37. + T cells in vivo. J Immunol 170 (2003) 2540-2548
38. Shimizu K., Kurosawa Y., Taniguchi M., Steinman R.M., and Fujii S. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 204 (2007) 2641-2653
39. Toura I., Kawano T., Akutsu Y., Nakayama T., Ochiai T., and Taniguchi M. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 163 (1999) 2387-2391
40. Motohashi S., Nagato K., Kunii N., Yamamoto H., Yamasaki K., Okita K., et al. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182 (2009) 2492-2501
41. Ishikawa E., Motohashi S., Ishikawa A., Ito T., Uchida T., Kaneko T., et al. Dendritic cell maturation by CD11c-T cells and Vα24+ natural killer T-cell activation by α-galactosylceramide. Int J Cancer 117 (2005) 265-273
42. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11 (2005) 1910-1917
43. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Hanaoka H., et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12 (2006) 6079-6086
44. Motohashi S., and Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 99 (2008) 638-645
45. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99 (2002) 1259-1266
46. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
47. Socinski M.A. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am 9 (2003) 207-236
48. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
49. Huisman C., Smit E.F., Giaccone G., and Postmus P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18 (2000) 3722-3730